# Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma

> **NCT02293005** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 28 (actual)

## Conditions studied

- Lung Cancer
- Mesothelioma

## Interventions

- **DRUG:** Alisertib

## Key facts

- **NCT ID:** NCT02293005
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05-20
- **Primary completion:** 2021-07-06
- **Final completion:** 2021-07-06
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2022-10-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02293005

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02293005, "Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02293005. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*